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Abstract
Motivation. Non-invasive prenatal testing or NIPT is currently among the top re-
searched topic in obstetric care. While the performance of the current state-of-the-art
NIPT solutions achieve high sensitivity and specificity, they still struggle with a consid-
erable number of samples that cannot be concluded with certainty. Such uninformative
results are often subject to repeated blood sampling and re-analysis, usually after two
weeks, and this period may cause a stress to the future mothers as well as increase the
overall cost of the test.
Results. We propose a supplementary method to traditional z-scores to reduce the
number of such uninformative calls. The method is based on a novel analysis of the
length profile of circulating cell free DNA which compares the change in such profiles
when random-based and length-based elimination of some fragments is performed. The
proposed method is not as accurate as the standard z-score; however, our results suggest
that combination of these two independent methods correctly resolves a substantial por-
tion of healthy samples with an uninformative result. Additionally, we discuss how the
proposed method can be used to identify maternal aberrations, thus reducing the risk of
false positive and false negative calls.
Availability and Implementation. A particular implementation of the proposed
methods is not provided with the manuscript.
Contact. Correspondence regarding the manuscript should be directed at Frantisek
Duris (fduris@dcs.fmph.uniba.sk).
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Supplementary Information. No additional supplementary information is avail-
able.
Keywords: Next-generation sequencing, Cell-free DNA, Uninformative result, Method,
Trisomy, Prenatal testing
1 Introduction
Prenatal screening and diagnostics are important parts of obstetric care. Current methods
of prenatal testing still involve most commonly invasive sampling of fetal material using
procedures such as amniocentesis and chorionic villus sampling which are associated with a
small but real risk of miscarriage 0.5− 1% (Mujezinovic and Alfirevic, 2007). To prevent the
risk of abortion associated with invasive sampling procedures, non-invasive prenatal testing
(NIPT) based on fetal DNA analysis from maternal circulation has been developed. In 1997,
the discovery of fetal cell-free DNA (cfDNA) in maternal plasma and serum revolutionized the
area of non-invasive prenatal diagnostics, and opened up new options in the field of obstetric
research (Lo et al., 1997). The fetal cfDNA is of placental origin (Bischoff et al., 2005), and
it can be reliably detected from fifth week of gestation (Lo et al., 1998). On average, the fetal
cfDNA contributes about 10% of all cfDNA fragments circulating in woman’s blood when
sampling is carried out between 10 and 20 gestational weeks, although the variance is quite
large (Fiorentino et al., 2016). The advance of massively parallel sequencing technologies
together with the rapid development of bioinformatic algorithms and tools ushered in a new
era of non-invasive prenatal identification of common fetal aneuploidies, now commonly known
as NIPT (Chiu et al., 2008; Fan et al., 2008; Chiu et al., 2011; Sehnert et al., 2011; Bianchi
et al., 2012; Straver et al., 2013; Stephanie et al., 2014; Tynan et al., 2016).
While the performance of the current state-of-the-art NIPT solutions achieve high sensi-
tivity and specificity (Bianchi et al., 2014; Koumbaris et al., 2016), they still struggle with a
considerable number of samples that cannot be concluded with certainty. The great source
of such uninformative samples is in the nature of the statistical testing. Considering stan-
dard cut-off threshold 2.5 for reliable conclusion of healthy samples (Bianchi et al., 2014),
and testing normally distributed ratios measured for the common aneuploidy chromosomes,
the chance that a healthy sample would achieve z-score greater than this is around 1.86%,
and it is even higher when testing for other aberrations such as monosomy, gonosomal or
sub-chromosomal aberrations.
Other problems are represented by maternal DNA aberrations such as maternal mosaicism
(Wang et al., 2014), unidentified maternal tumors (Amant et al., 2015), or copy number
variations (Snyder et al., 2015; Zhou et al., 2017). Hypothetically, a duplication of even
a small part of maternal chromosome, which may not be detrimental for the mother, may
result in a false positive call for fetal aneuploidy. This is because such duplication effectively
increases the size of that chromosome, and, because maternal cfDNA is by far dominant, the
signal from partial maternal duplication can be interpreted as full fetal trisomy. Similarly, an
opposite effect can cause a false negative result.
There is a growing body of studies addressing this issue (Wang et al., 2014, 2015b,a).
A particularly interesting venue of research focuses on qualitative differences between fetal
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and maternal cfDNA fragments, namely their lengths. It was previously reported that fetal
fragments are on average shorter than maternal (Fan et al., 2010; Stephanie et al., 2014;
Minarik et al., 2015). Using this information, Shubina et al. (2017) were able to identify, post
test, which of the false positive trisomy X samples were due maternal mosaicism. Briefly, they
observed that in case of true fetal aneuploidy, the fetal fraction calculated from X chromosome
increases when the long reads are filtered out. On the other hand, for maternal mosaicism
the filtering has almost no effect on this fetal fraction.
Extending the above mentioned work, in this paper we present a method to further boost
the elimination of uninformative results which have a potential to cause needless stress to
the parents, requiring repeated blood samplings and analyzes. The associated increase of ex-
penses, in turn, lower viability of the NIPT product. Reducing such cases is, therefore, of high
interest in the area of NIPT. Our method is also based on the length of cfDNA fragments,
taking into account how fragments of a particular length contribute to the z-score calculated
from some chromosomes as in (Sehnert et al., 2011). Even if the proposed method is not as ac-
curate as the standard z-score, our results suggest that combination of these two independent
methods correctly resolves a substantial portion of healthy samples with an uninformative
result. Additionally, we discuss application of the novel method for distinguishing between
fetal (e.g., aneuploidy) and maternal signal (e.g., copy number variation).
2 Material and methods
2.1 Sample acquisition
We have collected altogether 2,621 samples with singleton pregnancy, of which 2,569 were
negative for trisomy of chromosomes 13, 18 and 21, while 5 were confirmed as T13, 6 were
confirmed as T18, and 39 were confirmed as T21. One negative sample (analyzed twice) was
falsely reported as T18. The samples were predominantly of Slovak and Czech origin. All
women participating in this study gave informed written consent consistent with the Helsinki
declaration.
2.2 Sample preparation and sequencing
Blood from pregnant women was collected into EDTA tubes and kept at 4◦C temperature until
plasma separation. Blood plasma was separated within 36 hours after collection and stored at
−20◦C unit DNA isolation. DNA was isolated using Qiagen DNA Blood Mini kit. Standard
fragment libraries for massively parallel sequencing were prepared from isolated DNA using
an Illumina TruSeq Nano kit and a modified protocol described previously (Minarik et al.,
2015). Briefly, to decrease laboratory costs, we used reduced volumes of reagents what was
compensated by 9 cycles of PCR instead of 8 as per protocol. Physical size selection of cfDNA
fragments was performed using specific volumes of magnetic beads in order to enrich fetal
fraction. Illumina NextSeq 500/550 High Output Kit v2 (75 cycles) was used for massively
parallel sequencing of prepared libraries using pair-end sequencing with read length of 2x35bp
on an Illummina NextSeq 500 platform.
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2.3 Mapping and read count correction
Sequencing reads were aligned to the human reference genome (hg19) using Bowtie 2 algorithm
(Langmead et al., 2009). The first stage of data processing was carried out as previously
described (Minarik et al., 2015). NextSeq-produced fastq files (two per sample; R1 and R2)
were directly mapped using the Bowtie 2 algorithm with very-sensitive option. Unless stated
otherwise, only randomly chosen 5 million of alignments for each sample were considered,
thus reducing the between-sample variability induced by sequencing. Reads with mapping
quality of 40 or higher were retained for further data processing. Next, for each sample the
unique reads were processed to eliminate the GC bias according to (Liao et al., 2014) with
the exclusion of intrarun normalization. Briefly, for each sample the number of unique reads
from each 20kbp bin on each chromosome was counted. With empty bins filtered out, the
locally weighted scatterplot smoothing (LOESS) regression was used to predict the expected
read count for each bin based on its GC content. The LOESS-corrected read count for a
particular bin was then calculated as RCcor = RC − |RCloess − RCavg|, where RCavg is the
global average of read counts through all bins, RCloess is the fitted read count of that bin,
and RC is its observed read count.
Furthermore, variability of human genome in population also contributes to the mapping
bias, mainly in regions with common structural differences. At first, bin counts were trans-
formed into a principal space, where the first component represented the highest variability
across individuals in the control set. To normalize the sample, bin counts corresponding
to predefined number of top components were removed to reduce common noise in euploid
samples (Price et al., 2006; Zhao et al., 2015; Johansson et al., 2017).
2.4 Reference z-score calculation
The reference z-scores of samples were calculated as normalized chromosome values (NCV)
according to Sehnert et al. (2011). Given our training set, the optimal reference chromosomes
were determined to be 1, 4, 8, 10, 19 and 20 for trisomy 21, 4, 7, 8, 9, 10 and 16 for trisomy
18, and 3, 4 and 7 for trisomy 13. Similarly to (Bianchi et al., 2012), samples scoring 4 and
higher were considered trisomic, while samples scoring 2.5 or lower were considered euploid.
The range (2.5, 4) was considered uninformative. We will refer to these NCV values as
reference z-scores or ZNCV .
2.5 Length score calculation
We defined three novel statistics based on the fragment lengths, each building on the pre-
vious one. The basis for our first novel statistic, termed λ-score, were read counts for the
chromosome of interest (e.g., the usual 13th, 18th or 21st chromosome). However, in contrast
with the traditional z-scores, we did not compare the read count with the expected normal
value estimated from a set of euploid samples. Instead, we continuously eliminated fragments
of certain length and compared the observed counts with the expected counts, if the same
amount of fragments was eliminated randomly.
More particularly, if i marks the chromosome of interest and chri the number of reads
mapped to the ith chromosome of the tested sample, then let chri(l) be the number of reads
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mapped to the ith chromosome that are of length at most l. Furthermore, let the total number
of reads of the sample be n, and let nl be the total number of reads that are of length at
most l. The number of reads mapped to the ith chromosome (of any length) after uniform
random elimination follows a binomial distribution with parameters (nl, p), p = chri/n. The
ratio chri/n gives the proportion of reads originally mapped to the ith chromosome, and the
number nl gives the number of reads to be drawn. Thus, the expected number of reads mapped
the ith chromosome after the uniform random draw and its variance is equal to el = nlp and
vl = nlp(1− p) as in binomial distribution, respectively.
For each sample and chromosome, we defined a series of λ-scores as
λi(l) =
chri(l)− nlp√
nlp(1− p)
, (1)
where l ranges from 50 to 200 and i indicates a chromosome. Next, we defined a second novel
statistic termed FL-score as
FLi = max
125≤l≤145
λi(l). (2)
The bounds 125 and 145 were determined empirically. Finally, the FL-scores were normalized
into z-scores which approximately follow standard normal distribution for euploid samples.
Then, for any sample, its normalized FL-score value ZFL was used as an alternative method
for the prediction of aneuploidy.
2.6 Combining the scores
In our analysis, we found no correlation between the reference (ZNCV ) and length-based
(ZFL) scores measured in our training set of euploid samples (Pearson R = 0.017, p = 0.129).
Thus, we considered them as two independent random variables, each from a standard normal
distribution. The sum of their squares follows a chi-squared distribution with 2 degrees of
freedom, and a survival function of the chi-squared distribution was used to associate this
sum with the probability. Finally, this probability was converted back to a standard score
ZNCV+FL through quantile function for easy comparison with other methods. Note that the
calculations were performed in log-space to overcome underflow issues.
On the other hand, there was a significant correlation between ZSZ (defined below in
section 3.2) and ZFL (Pearson R = 0.55, p < 0.001). In this case, we combined them according
to (Owen and Chmielewski, 1985). Specifically, we first performed a principal component
analysis of the pairs (ZSZ , ZFL). Then, we recalculated the z-scores along the newly found
eigenvectors e1, e2 using the respective eigenvalues as new variances. The resulting scores
were two independent standard normals, and we proceeded to combine them as in the first
paragraph of this section. The resulting z-score was marked as ZSZ+FL (Figure 1).
2.7 Statistical analysis
The significance of our findings was evaluated using statistical tests implemented in Python
scipy package (Jones et al., 2014). The linear dependency of the two scores in negative
samples was calculated with Pearson correlation. Since scores of aberrant samples were not
normally distributed, Wilcoxon signed-rank test was used to estimate statistical significance
of improvement between the reference and proposed methods.
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(a) Combination of statistically independent NCV and FL scores.
The scores were combined through χ2 distribution with 2 degrees
of freedom (section 2.6).
(b) Combination of statistically dependent SZ and FL scores. First,
principal component analysis was used to calculate axes (e1, e2) of
variation along which the two principal components were indepen-
dent. Subsequently, χ2 distribution with 2 degrees of freedom was
used to combine the principal components (section 2.6).
Figure 1: Combination of novel FL score with the reference score NCV (1a) and length-
reduced reference score SZ (1b). Displayed are negative samples for chromosome 21. The
ellipses represent combined z-scores 2.5 and 4, respectively.
6
3 Results
3.1 λ−score profiles
First, we calculated series of λ-scores for euploid and trisomic samples for chromosomes 13,
18 and 21, and length range from 50bp to 220bp. We observed that trisomic samples behaved
differently than euploid samples (Figure 2). This difference can be explained by fetal fragments
being shorter than maternal. The fetal and maternal cfDNA differ in properties such as length
distribution and source chromosomes (Fan et al., 2010; Stephanie et al., 2014). Originally,
they are mixed in some ratio, usually termed fetal fraction, resulting in the observed properties
of the mixture (read length distribution and chromosome mapping ratios). Uniform random
elimination of fragments preserves these properties of the mixture on account of being uniform,
both in euploid and trisomic cases. On the other hand, elimination by length as described
in section 2.5 eliminates more maternal than fetal fragments on account of the latter being
shorter than the former. Thus, the original properties of the mixture are not preserved, if
fetal and maternal properties are not the same, which is the case for trisomic samples with
respect to chromosome mapping ratios.
At first, the λ-scores of trisomic samples gradually increase with the elimination of longer
fragments. This positive effect is however balanced by the negative effect of lower number
of remaining fragments, and so, after while, the λ-scores decline to the values expected by
a random draw. We observed the highest deviation of aberrant samples using thresholds for
fragment lengths between 125bp and 145bp. We therefore measured the maximal value in
this range which we termed FL score of the sample.
Note that in contrast with the reference z-score ZNCV , the calculation of λ-scores is not
based on comparison of proportions of fragments with healthy population. An excessive
number of fragments from a chromosome would therefore not result in the positive call, if
these fragments do not have fetal length distribution. Thus, it is possible to reveal false
positive calls caused by maternal aberrations. Similar concepts have been already utilized in
distinction between maternal and fetal gonosomal aberrations (Shubina et al., 2017), leading
to the reduction of false positive results of the monosomy X0 predictions (section 3.5).
3.2 In silico size selection
Next, we examined the effect of the length-based fragment filtering on the reference z-scores.
Particularly, we first calculated the reference z-scores ZNCV (section 2.4), and then we removed
the fragments longer than 150bp. However, this considerably changed the read count for our
samples (1.5 ± 0.3 million), so we concluded that the trained mean and standard deviation
(used in z-score calculation) for the original data may not be suitable for the length-reduced
data. Therefore, we applied this length-reduction to our training samples as well, determined
the new mean and standard deviation (we kept the reference chromosomes the same), and only
with these new values we calculated z-scores of the length-reduced test samples. Comparing
the original and length-reduced z-scores (Figure 3), we observed only small and statistically
insignificant increase in z-scores of trisomic samples (average multiplicative increase 1.05×;
Wilcoxon Z = 516, p < 0.241). For future reference, we termed these z-scores ZSZ .
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Figure 2: Deviation of the T21 positive samples from the euploid samples in terms of λ-
score. Elimination of fragments with length above a threshold (Fragment length limit) leads
to divergence of chromosomal counts from the expectations. In the healthy samples (only
500 samples shown for clarity), the difference can be explained by fluctuations in random
draw. On the other hand, aberrant samples show profile that markedly diverge from expected
values.
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On the other hand, when all aligned reads were considered (recall that up until now, all
samples were restricted to the first 5 million raw alignments, see section 2.3), and the same
procedure was applied again, the increase in z-scores of trisomic samples became statistically
significant (average multiplicative increase 1.13×; Wilcoxon Z = 136, p < 0.001). As before,
we recalculated the mean and standard deviation used in the z-score calculation because of
the changed read count per sample (8.8± 4.6 million), while the reference chromosomes were
again kept the same (section 2.4).
This finding indicates that the length-based fragment selection is beneficial only for sam-
ples with more than 5 million aligned fragments, at least for the reference z-scores. This
is in accord with our previous findings that in silico size-based filtering of fragments (only
reads up to 155bp were retained) did not lead to statistically significant increase in trisomic
z-scores using MiSeq runs having 3.1± 1.0 million reads per sample, while statistically signif-
icant (p = 0.04) increase was observed for samples sequenced on Ion Torrent PGM, of which
samples had 5.8± 1.0 million reads (Minarik et al., 2015).
3.3 Combined scores as supplemental evaluation method
The performance of the novel statistic ZFL by itself was observed to be weaker than that
of the traditional ZNCV (Figure 3). Particularly, there was a substantial decrease in z-
scores for trisomic samples. On the other hand, their combination ZNCV+FL resulted in
statistically significantly higher trisomic z-scores than ZNCV (average multiplicative increase
1.11×; Wilcoxon Z = 17, p < 0.001). Surprisingly, the combined score ZSZ+FL produced only
statistically insignificant increase of trisomic z-scores (average multiplicative increase 1.02×;
Wilcoxon Z = 637, p > 0.05).
Furthermore, we observed a decrease of ZSZ+FL scores of false positive and uninformative
samples when compared with reference ZNCV , even though other samples that were previously
classified as negative replaced them in the uninformative range. Additionally, ZNCV+FL and
ZSZ+FL resulted both in false positive results indicating that using these metrics alone may
decrease accuracy of the testing.
3.4 Improved evaluation method
In light of our findings, we propose a following improvement of the NIPT evaluation process.
First, a reference ZNCV is calculated. If it is in the negative zone, then no further test is
applied and the sample is closed as normal. If the ZNCV is in the uninformative zone, then
ZSZ+FL is computed, and if this new score is in the negative zone, the sample is closed as
normal. Our findings indicate that this process considerably decrease the number of uninfor-
mative results (Figure 3, the white marks in particular).
3.5 A false positive sample
We observed a atypical sample from IVF pregnancy (analyzed twice) with high risk for trisomy
18 (Figure 4). Although both analyzes were supported by solid ZNCV scores 6.82 and 6.31,
the predicted aberration was not confirmed by invasive follow-up test. On the other hand,
the fragment length ZFL score classified it as healthy sample (-0.57, 0.34). The combination
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Figure 3: Comparison of z-score calculation methods on chromosome 21 (upper), chromosome
18 (middle) and chromosome 13 (lower). Reference method based on chromosomal fragment
counts (NCV) performs better than proposed FL method, albeit their combination (NCV +
FL) increased z-scores of trisomic samples (black marks). Size selection (SZ) further improves
z-scores of trisomic samples. The combination with FL method (SZ + FL) most markedly
reduces z-scores of samples evaluated as uninformative using traditional NCV score alone
(white marks). Empty shapes represent results of the two analyzes of the IVF sample discussed
in section 3.5.
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Figure 4: λ-scores for chromosome 18. Interesting is the twice analyzed false positive T18
sample discussed in section 3.5. The λ profile, similar to healthy samples, may indicate that
the revealed aberration by ZNCV (6.82 and 6.31) may be mistaken.
of these scores Zchi led to a slightly reduced scores (6.43, 5.88), and the inclusion of the in
silico size selection further reduced their z-scores (3.64, 3.44), getting them into uninformative
range.
The most likely explanation is that this was a result of a maternal copy number variation
on the 18th chromosome which is known to cause false positive results (Zhou et al., 2017).
Unfortunately, we were not able to perform a follow-up of maternal genotype. If this was
the case, it would indicate that the proposed method, particularly the λ profiles, can be used
to distinguish between fetal (e.g., aneuploidy) and maternal (e.g., copy number variation)
NIPT signals. Such method would be very valuable, but validation on a larger cohort of such
samples is required.
Other possible and rather interesting hypothesis is that this was the case of a trisomic
vanishing twin. In this case, we would expect that the cfDNA fragment length distribution
originating from the trisomic vanishing twin would be similar to that of the trisomic living
fetus, though we were not able to find publications supporting or opposing this expectation.
However, the observation indicates that the fragment length distribution is similar to that
of a mother. Thus, either the vanishing twin hypothesis or the assumption about the read
length distribution is wrong. In case of the latter, such difference could then be utilized for
reducing the false NIPT results due to vanishing twin effects.
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4 Conclusion
The reference z-score method (ZNCV ) of aneuploidy prediction based on chromosomal pro-
portions is already widely accepted, since it can quite well separate between trisomic and
euploid samples. To avoid false predictions in routine diagnosis, NIPT tests have typically
a range of scores which are considered too risky for definite predictions. Such uninforma-
tive results are often subject to repeated blood sampling and re-analysis, usually after two
weeks, and this period may cause a stress to the future mothers. In addition to that, high
numbers of uninformative results also increase the overall cost of the whole procedure. The
supplementary scores proposed in this paper may offer a useful way for reducing the number
of uninformative samples in several ways.
In our data set, we classified 53 of 2,569 (2.06%) negative samples as uninformative using
the reference ZNCV method. The combination of ZNCV with the ZFL score, ZNCV+FL, led
to similar number 51 (1.98%), albeit only 15 of them were shared in both metrics. The addi-
tion of size selection to the combined method (ZSZ+FL) increased number of uninformative
samples to 48 (1.87%) but only 4 of them were shared with the reference method. Thus, the
combination of these approaches can be used to substantially reduce the number of uninfor-
mative results as proposed in section 3.4. In our case, 49 out of 53 uninformative samples
would be closed as negative without affecting the prediction of true positive samples.
Another way to lower the number of uninformative samples is to classify uninformative
samples with low ZFL score as negative. Setting the threshold for ZFL score to 0, 1, 2 led
to correct elimination of 24 (45.28%), 41 (77.36%) and 50 (94.34%) out of 55 true negative
samples with uninformative ZNCV call. The thresholds, however, must be chosen with caution,
since the lowest observed ZFL score of positive sample was 1.34. Because this sample also
had high chromosomal ZNCV score 11.02, the false negative call with ZFL threshold set to
2 could be avoided by preferring the reference method, albeit similarly low ZFL scores may
occur along with the low score of the reference method.
A typical NIPT analysis is suitable for prediction of monosomy as well. The monosomic
samples are distinguished by negative z-scores below some predefined threshold, for example
−3 (Mazloom et al., 2013). In contrast with the sign of chromosomal ZNCV score, which
indicate increase or decrease of DNA material from specific chromosome, the sign of the
fragment length ZFL score indicates maternal or fetal origin of the aberration. This way, the
scores may be divided into four categories representing: 1) maternal duplication (ZFL < 0,
ZNCV > 0), 2) fetal duplication (ZFL > 0, ZNCV > 0), 3) maternal deletion (ZFL < 0,
ZNCV < 0), and 4) fetal deletion (ZFL > 0, ZNCV < 0), thus making the prediction more
informative (see Figure 5).
Also, we observed a statistically significant increase in trisomic z-scores for method ZNCV+FL.
Thus, this method can be considered as an improved version of ZNCV .
Finally, we discuss the possibility of either our method being able to distinguish between
fetal and maternal NIPT signals or trisomic vanishing twin having different cfDNA fragment
length distribution than living trisomic fetus. To verify these hypotheses, more tests on a
larger cohort of samples are required.
Elimination of long fragments may significantly improve prediction accuracy of trisomy
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Figure 5: Comparison of z-scores calculated chromosomal count (NCV) and fragment length
(FL) methods. Positive (black) and negative (white) samples with z-scores higher that 2.5
(NCV method) are represented by triangles (chromosome 21), diamonds (chromosome 18)
and circles (chromosome 13). Other negative samples are accumulated in form of a density
plot in the intersection of major axes (x = 0; y = 0). Major axes divide predictions into
four classes, while the fetal trisomies are located in top, right quartile (ZFL > 0, ZNCV > 0).
Empty shapes represent results of the two analyzes of the IVF sample discussed in section
3.5.
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testing. The number of sequenced DNA fragments must be however sufficient to balance the
lower number of analyzed fragments. Based on the patterns observed in z-score profiles, we
designed a novel method for prediction that is independent to standard method based on
chromosomal counts. We presented that combination of these two methods may conclude
samples that cannot be safely classified using a single method.
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